Head to head
Linaclotide against Plecanatide
Two approved oral peptides for constipation-predominant IBS and chronic idiopathic constipation, both acting on the same receptor in the gut lining without being absorbed. Plecanatide is marketed on better tolerability, and that specific claim has never been tested against linaclotide in a head to head trial.
Column A
LinaclotideLinaclotide (Linzess), guanylate cyclase-C agonist
A 14-amino-acid peptide taken orally that works without being absorbed, acting entirely on receptors in the gut lining. Approved on randomised phase 3 trials for constipation.
Column B
PlecanatidePlecanatide (Trulance), uroguanylin analogue and guanylate cyclase-C agonist
An oral 16-amino-acid uroguanylin analogue approved in 2017 for chronic idiopathic constipation and irritable bowel syndrome with constipation. In its pivotal phase 3, 20.1 percent of patients on 3 mg were durable responders versus 12.8 percent on placebo, a 7.3 point absolute difference. Its claimed tolerability advantage over linaclotide has never been tested head to head.
Side by side, on the facts we can check
| Attribute | Linaclotide | Plecanatide |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| FDA status | FDA-approved as Linzess for irritable bowel syndrome with constipation and for chronic idiopathic constipation in adults, and for functional constipation in children. Carries a boxed warning against use in children under two years because of a risk of serious dehydration. | FDA-approved on 19 January 2017 under NDA 208745, marketed as Trulance, for chronic idiopathic constipation and for irritable bowel syndrome with constipation in adults. Contraindicated in patients under six years of age because of the risk of serious dehydration, and its use is avoided in children aged six to under 18. Not approved for weight loss, for gut permeability or leaky gut, or for any general digestive health use. |
| Half-life | Not meaningfully described systemically, because absorption is minimal by design. The peptide and its active metabolite act locally in the gut lumen and are degraded there. | Not calculable. The label states that a half-life could not be determined, because systemic absorption is minimal and the drug acts on receptors facing into the gut lumen. |
| Molecular weight | Roughly 1.5 kDa. A 14-amino-acid peptide with three disulfide bonds. | About 1682 Da. Sixteen amino acids. |
| Mechanism | A 14-amino-acid peptide agonist at guanylate cyclase-C on the apical surface of intestinal enterocytes, mimicking the endogenous peptides guanylin and uroguanylin. Activation raises intracellular and extracellular cyclic GMP, which activates the cystic fibrosis transmembrane conductance regulator chloride channel, driving chloride and bicarbonate into the lumen with sodium and water following. That increases intestinal fluid and accelerates transit. The extracellular cyclic GMP is also thought to reduce visceral pain by acting on submucosal afferent nerves, which is the proposed explanation for the pain benefit in irritable bowel syndrome as distinct from the laxative effect. | Agonism at guanylate cyclase-C on the luminal surface of intestinal epithelial cells. Receptor activation raises intracellular cyclic GMP, which activates the cystic fibrosis transmembrane conductance regulator and drives chloride and bicarbonate into the gut lumen, pulling water with them. The result is softer stool and faster transit. Cyclic GMP also crosses to the basolateral side, where it is thought to reduce afferent nociceptor firing, which is the proposed basis for the abdominal pain benefit in irritable bowel syndrome. Because plecanatide is derived from uroguanylin, its activity is greater at the slightly acidic pH of the proximal small intestine, which is the claimed point of difference from linaclotide. |
| Human studies cited | 1 | 2 |
| Legal status, US | FDA-approved, prescription only | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Linaclotide and Plecanatide?
Linaclotide: A 14-amino-acid peptide taken orally that works without being absorbed, acting entirely on receptors in the gut lining. Approved on randomised phase 3 trials for constipation. Plecanatide: An oral 16-amino-acid uroguanylin analogue approved in 2017 for chronic idiopathic constipation and irritable bowel syndrome with constipation. In its pivotal phase 3, 20.1 percent of patients on 3 mg were durable responders versus 12.8 percent on placebo, a 7.3 point absolute difference. Its claimed tolerability advantage over linaclotide has never been tested head to head.
Which has stronger research evidence, Linaclotide or Plecanatide?
This database does not grade compounds. It counts what was run in people: 1 of the 1 studies cited on the Linaclotide profile were human work, against 2 of 3 for Plecanatide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Linaclotide and Plecanatide FDA-approved?
Linaclotide: FDA-approved as Linzess for irritable bowel syndrome with constipation and for chronic idiopathic constipation in adults, and for functional constipation in children. Carries a boxed warning against use in children under two years because of a risk of serious dehydration.. Plecanatide: FDA-approved on 19 January 2017 under NDA 208745, marketed as Trulance, for chronic idiopathic constipation and for irritable bowel syndrome with constipation in adults. Contraindicated in patients under six years of age because of the risk of serious dehydration, and its use is avoided in children aged six to under 18. Not approved for weight loss, for gut permeability or leaky gut, or for any general digestive health use..
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.